Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mora, E. M.
Right arrow Articles by Johnston, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mora, E. M.
Right arrow Articles by Johnston, D. A.

Annals of Surgical Oncology, Vol 3, Issue 2 162-168, Copyright © 1996 by Society of Surgical Oncology

ARTICLES

Aggressive therapy for locoregional recurrence after mastectomy in stage II and III breast cancer patients

E. M. Mora, S. E. Singletary, A. U. Buzdar and D. A. Johnston
Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.

BACKGROUND: To determine if aggressive treatment of locoregional recurrence affects survival, we retrospectively analyzed the clinical outcome of 69 breast cancer patients who developed locoregional disease as their first episode of recurrence following mastectomy and adjuvant chemotherapy. METHODS: Patients were identified from among 1,707 stage II and III breast cancer patients who enrolled in five different doxorubicin-based adjuvant chemotherapy protocols at The University of Texas M. D. Anderson Cancer Center from 1975 to 1986. Sixty-nine evaluable patients who had a locoregional recurrence as the first site of relapse after mastectomy formed the study group. Multifactorial analysis of clinical and histopathological characteristics of both the primary tumor and the subsequent recurrence was performed using a logistic regression method. Survival analysis was performed using an actuarial life-table method calculated from the date of registration into the adjuvant therapy protocols. RESULTS: Median follow-up was 6.6 years. Two factors significantly affected survival: recurrence of disease during or after adjuvant treatment of the primary and whether the patient was rendered disease free after recurrence. CONCLUSIONS: Stage II and III breast cancer patients who have locoregional recurrence after adjuvant chemotherapy and can be rendered disease free may have a better survival rate. Aggressive treatment of locoregional recurrence including complete surgical excision should be considered in this subgroup of patients.


This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
G. Friedel, T. Kuipers, J. Dippon, F. Al-Kammash, T. Walles, T. Kyriss, S. Veit, M. Greulich, and V. Steger
Full-thickness resection with myocutaneous flap reconstruction for locally recurrent breast cancer.
Ann. Thorac. Surg., June 1, 2008; 85(6): 1894 - 1900.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
A. Chagpar, F. Meric-Bernstam, K. K. Hunt, M. I. Ross, M. Cristofanilli, S. E. Singletary, T. A. Buchholz, F. C. Ames, S. Marcy, G. V. Babiera, et al.
Chest Wall Recurrence After Mastectomy Does Not Always Portend a Dismal Outcome
Ann. Surg. Oncol., July 1, 2003; 10(6): 628 - 634.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the Society of Surgical Oncology.